KYMERA THERAPEUTICS INC's ticker is KYMR and the CUSIP is 501575104. A total of 129 filers reported holding KYMERA THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.46 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $890,545 | -80.5% | 29,834 | -73.7% | 0.00% | -100.0% |
| Q1 2024 | $4,557,353 | +537.3% | 113,367 | +303.6% | 0.00% | – |
| Q4 2023 | $715,145 | +40.5% | 28,089 | -23.3% | 0.00% | – |
| Q3 2023 | $509,115 | -27.2% | 36,627 | +20.4% | 0.00% | – |
| Q2 2023 | $699,586 | -87.5% | 30,430 | -83.9% | 0.00% | -100.0% |
| Q1 2023 | $5,614,470 | +1567.1% | 189,486 | +1304.3% | 0.00% | – |
| Q4 2022 | $336,785 | +14.6% | 13,493 | -0.0% | 0.00% | – |
| Q3 2022 | $294,000 | +10.1% | 13,496 | -0.5% | 0.00% | – |
| Q2 2022 | $267,000 | -58.9% | 13,563 | -11.8% | 0.00% | – |
| Q1 2022 | $650,000 | -32.8% | 15,371 | +1.0% | 0.00% | – |
| Q4 2021 | $967,000 | +7.0% | 15,225 | -1.1% | 0.00% | – |
| Q3 2021 | $904,000 | +100.9% | 15,396 | +66.2% | 0.00% | – |
| Q2 2021 | $450,000 | – | 9,264 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Atlas Venture Life Science Advisors, LLC | 5,350,422 | $159,710,097 | 16.82% |
| Aquilo Capital Management, LLC | 328,743 | $9,812,979 | 9.46% |
| BVF INC/IL | 5,161,801 | $154,079,760 | 4.32% |
| Redmile Group, LLC | 1,579,275 | $47,141,359 | 2.85% |
| Deer Management Co. LLC | 415,895 | $12,414,466 | 2.55% |
| Artal Group S.A. | 3,005,610 | $89,717,459 | 2.29% |
| Baker Brothers Advisors | 5,995,928 | $178,978,451 | 2.29% |
| Avoro Capital Advisors LLC | 3,888,888 | $116,083,307 | 1.55% |
| Checkpoint Capital L.P. | 82,000 | $2,447,700 | 1.48% |
| Deep Track Capital, LP | 1,500,000 | $44,775,000 | 1.34% |